Clinical utility of archived HIV-1 DNA sequencing: Optimizing antiretroviral therapy in patients with a suppressed HIV viral load by Holliday, Laura et al.
Clinical utility of archived HIV-1 DNA sequencing: optimizing antiretroviral 
therapy in patients with a suppressed HIV viral load 
OKLAHOMA STATE UNIVERSITY MEDICAL CENTER / PHARMACY
Laura Holliday, PharmD; Christina Connel, PharmD; Michael Hiebert, DO; John Bury, PharmD
INTRODUCTION
• Viral resistance testing is a cornerstone in 
HIV antiretroviral (ART) therapy
• Initiation of ART in wild type HIV without 
previous resistance involves a standard 
regimen of two nucleoside reverse 
transcriptase inhibitors (NRTIs) and a third 
antiretroviral medication with an alternate 
mechanism of action1
• Recommendations regarding regimen 
switching in the setting of virologic
suppression are not standardized, but take 
into account previous treatment failures, 
toxicities, and past resistance testing.
• Considerations regarding switching ART 
therapy include, but are not limited to, 
regimen simplification to reduce pill burden, 
side effects, drug interactions, and reduce 
costs
• Currently, there is only one genotypic assay 
(GA) available for patients with a viral load 
<500 copies per milliliter
• There is very little data surrounding the GA’s 
clinical significance or utility in practice.
• At this time, only one study has compared 
resistance patterns and ART class changes of 
the GA3
OBJECTIVES
The objectives of this study are to:
• Evaluate the number of patients with a 
suppressed viral load 3 and 6 months after 
switching their ART regimen based on GA 
results
• Investigate the clinical utility of the GA 
regarding patients with suspected resistance 
to their current antiretroviral therapy
• Identify the impact of GA results on those 
patients’ ART regimen and viral load.
Other specific aims of the study include:
• Identifying common indications for 
obtaining a GA
• Comparing ART pre- and post-GA ART 
regimens
• Evaluating mutations present on GA results
METHODS
This study is a retrospective chart review based on GA reports 
obtained historically through the Oklahoma State University 
Internal Medicine Specialty Clinic electronic medical record. 
Information gathered will consist of the following:
• Clinical indications for a GA
• Mutations on GA results (and on past resistance testing)
• ART regimen at the time of the GA draw
• ART regimen 3 and 6 months post-GA results
• Past ART regimens
Demographic information collected will included the following: 
patient age, sex, ethnicity, AIDS status, HIV risk category 
(intravenous drug use, men who have sex with men (MSM) 
heterosexual individuals, or other).
Other information gathered included CD4 count at the time the 
GA is obtained, CD4 count 3 and 6 months after a GA was 
obtained, HIV RNA at the time a GA was obtained, HIV RNA 3 
and 6 months after a GA was obtained, reported compliance to 
therapy, and patient-reported tolerability of ART regimens 
before and after a GA was obtained.
• GA results can be utilized to optimize the 
efficacy of  ART regimens for patients with 
HIV 
• Obtaining a GA provides guidance for ART 
regimen switches in the setting of patients 
who have developed resistance to their 
current ART regimen
• Further study will be conducted to compile 
mutations most commonly observed on GA 
reports, quantify incidence of pill burden 
reduction, and compare patient-reported  
medication adherence and ART regimen 
tolerability before and after switching 
therapy.
Data were gathered from 67 patients, primarily male (87%), 
with an average age of 45. The most common indications for 
obtaining a GA were baseline testing (29.8%), re-establishing 
care (25.4%), and history of non-adherence (20.9%). 
Approximately half (49%) of patients had an undetectable viral 
load 3 months after switching their ART regimen based on GA 
results.
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HIV-1 RNA obtained 
from host virus
HIV-1 RNA undergoes 
reverse transcription 
with viral cDNA
New HIV-1 DNA is 
amplified via PCR
DNA Amplification2
HIV-1 Genotyping2
• Amplified HIV-1 DNA is sequenced
• HIV-1 DNA sequence is compared to a wild-type reference 
sequence
• Mutations are interpreted using a proprietary archive of over 
100,000 HIV-1 genotype-phenotype matches gathered from other 
samples
• Interpretations are assessed as “resistant”, “resistance possible”, or 
“susceptible” and compiled into a report for the healthcare provider
• The report results are utilized to create a new ART regimen                 
for the patient
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